Walmart, Novo Nordisk Unveil Own Low-Cost Brand Insulin

by Vandana Singh, Benzinga Editor

June 29, 2021 8:51 AM | 1 min read |

Walmart Inc WMT is launching its first-ever private label insulin analog, available exclusively at its stores.
The company worked directly with manufacturer Novo Nordisk A/S NVO on ReliOn Novolog, allowing it to offer the product in both vials and FlexPens at a far lower price.
Walmart said the vials would retail for $72.88 and the FlexPens for $85.88, saving consumers between 58% and 75% off the cash price for other insulin products, equating savings of up to $101 per branded vial and $251 per package of branded FlexPens.
Customers will need a prescription from their physicians to switch to the new product.
Price Action: WMT stock is up 0.14% at $138.3, and NVO shares are up 0.9% at $84 during the premarket session on the last check Tuesday.

Posted In:

News Health Care Contracts General Briefs insulin

Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.